For instance, rosiglitazone markedly attenuates middle cerebral artery occlusion–mediated brain tissue loss and white matter injury via reducing the number of Iba1(+)/CD16(+) M1 microglia and increasing the number of Iba1(+)/CD206(+) M2 microglia after stroke (Han et al., 2015). Here, MRC1 is linked to stroke disorder.